NETWORK META-ANALYSIS DESIGN CONSIDERATIONS IN A COMPLEX AND RAPIDLY EVOLVING LANDSCAPE: A CASE STUDY IN FIRST-LINE (1L) ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)

被引：0
|
作者：
Popoff, E. [1 ]
Lozano-Ortega, G. [1 ]
Varol, N. [2 ]
Yuan, Y. [3 ]
Penrod, J. R. [3 ]
Goring, S. M. [1 ]
机构：
[1] Broadst HEOR, Vancouver, BC, Canada
[2] Bristol Myers Squibb, Uxbridge, Middx, England
[3] Bristol Myers Squibb, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN275
引用
收藏
页码：S471 / S471
页数：1
相关论文
共 50 条
  • [21] The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer
    Melosky, Barbara
    Wheatley-Price, Paul
    Juergens, Rosalyn A.
    Sacher, Adrian
    Leighl, Natasha B.
    Tsao, Ming-Sound
    Cheema, Parneet
    Snow, Stephanie
    Liu, Geoffrey
    Card, Paul B.
    Chu, Quincy
    LUNG CANCER, 2021, 160 : 136 - 151
  • [22] Identifying prognostic and predictive value of mutations associated with clinical outcomes in first line (1L) patients with advanced or metastatic non-small cell lung cancer (aNSCLC).
    Perez Parente, Diego
    Cobo-Dols, Manuel
    Hasan, Haroon
    Olson, Sara
    Pal, Navdeep
    Wilkinson, Samantha
    La Orden Tevar, Beatriz
    Perez Fernandez, Mar
    Provencio-Pulla, Mariano
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] TREATMENT EFFECT MODIFICATION OF IMMUNOTHERAPY-BASED REGIMENS IN FIRST-LINE (1L) ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC): A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS (RCTS)
    Goring, S. M.
    Waser, N.
    Varol, N.
    Penrod, J. R.
    Yuan, Y.
    Wang, S.
    VALUE IN HEALTH, 2020, 23 : S29 - S29
  • [24] Adverse event (AE) burden of nivolumab-based immunooncology (IO) therapy with/without chemotherapy (chemo) for first-line (1L) advanced non-small cell lung cancer (aNSCLC)
    Schwartzberg, L.
    Wu, A.
    Hartman, J.
    Wang, T.
    Yin, X.
    Chen, J.
    Betts, K. A.
    Lubinga, S. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1069 - S1070
  • [25] First-Line Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer (NSCLC) - A Network Meta-Analysis by PD-L1
    San Tan, P.
    Nazareth Aguiar Junior, P.
    Husnain, M.
    Haaland, B.
    Lopes, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S467 - S467
  • [26] Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis
    Li, Dan-Ni
    Lu, Wen-Qing
    Yang, Bo-Wen
    Zhang, Ling-Yun
    Jin, Bo
    Wang, Shuo
    Che, Xiao-Fang
    Li, Ce
    Liu, Yun-Peng
    Qu, Xiu-Juan
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [27] Canakinumab in combination with first-line (1L) pembrolizumab plus chemotherapy for advanced non-small cell lung cancer (aNSCLC): Results from the CANOPY-1 phase 3 trial.
    Tan, Daniel S.
    Felip, Enriqueta
    Castro, Gilberto
    Solomon, Benjamin J.
    Greystoke, Alastair
    Cho, Byoungchul
    Cobo, Manuel
    Kim, Tae Min
    Ganguly, Sandip
    Carcereny, Enric
    Paz-Ares, Luis
    Bennouna, Jaafar
    Garassino, Marina
    Schenker, Michael
    Kim, Sang-We
    Mookerje, Bijoyesh
    Passos, Vanessa Q.
    Deudon, Stephanie
    Dharan, Bharani
    Song, Yuanbo
    Caparica, Rafael
    Johnson, Bruce E.
    CANCER RESEARCH, 2022, 82 (12)
  • [28] First-line treatment for advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer: a network meta-analysis
    Zhang, Mengyao
    Sun, Lan
    FRONTIERS IN ONCOLOGY, 2025, 14
  • [29] First-line immunotherapy efficacy in advanced squamous non-small cell lung cancer with PD-L1 expression ≥50%: a network meta-analysis of randomized controlled trials
    Chen, Wei
    Liu, Hangmei
    Li, Yiwen
    Xue, Wenxin
    Fan, Shuo
    Sun, Jingbo
    Liu, Shui
    Liu, Yang
    Zhang, Lili
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [30] First-line Brigatinib in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer: A Network Meta-Analysis
    Lin, H.
    Cichewicz, A.
    Neupane, B.
    Wu, Y.
    Vinals, L.
    Fahrbach, K.
    Reckamp, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S659 - S660
12345